-
Bank of America Upgrades Optimer Pharmaceuticals To Buy, PT To $17
Monday, April 4, 2011 - 8:41am | 29Bank of America has upgraded Optimer Pharmaceuticals (NASDAQ: OPTR) from Neutral to Buy and has raised the price target from $14 to $17.
-
Piper Jaffray Reiterates Overweight Rating On WPI
Monday, April 4, 2011 - 8:36am | 97Piper Jaffray has issued a report reiterating and Overweight Rating on Watson Pharmaceuticals (NYSE: WPI). According to the report, "With KV significantly cutting the price of its weekly progesterone injectible for the prevention of pre-term birth, known as Makena, we do not envision a diminished...
-
Avanir Pharmaceuticals Announces Filing of IND for AVP-923 for the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis
Monday, April 4, 2011 - 8:34am | 80Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has filed an Investigational New Drug application with the U.S. Food and Drug Administration to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients...
-
Benzinga's Top Pre-Market NASDAQ Gainers (VVUS, OREX, CIGX, TEVA)
Monday, April 4, 2011 - 8:21am | 136VIVUS Inc (NASDAQ: VVUS) shares surged 15.69% to $7.30 in the pre-market session. VVUS reported that its weight loss drug Qnexa helped lowering blood pressure levels. Orexigen Therapeutics Inc (NASDAQ: OREX) shares advanced 6.94% to $3.08 in the pre-market session. OREX presented additional...
-
Sanofi Gets Control On Genzyme, CVR's Starting To Trade (SNY, GENZ)
Monday, April 4, 2011 - 8:16am | 275Sanofi-Aventis (NYSE: SNY) said it now has Genzyme (NASDAQ: GENZ) under its control, and the contingent value rights (CVR) are going to start trading today under the "GENZ" ticker. Genzyme and Sanofi-Aventis have been the subject of much press over the recent months as Sanofi-Aventis had bid for...
-
Pfizer To Sell Capsugel Unit To KKR For $2.38 billion
Monday, April 4, 2011 - 8:09am | 124Pfizer Inc (NYSE: PFE) agreed to sell its Capsugel unit to private equity firm KKR & Co (NYSE: KKR) for around $2.38 billion. As a result of the sale of its Capsugel unit, Pfizer slightly reduced its revenue projections for this year and next year. PFE now projects its FY11 revenue of $65.2...
-
Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
Monday, April 4, 2011 - 7:38am | 87Abbott (NYSE: ABT) and Enanta Pharmaceuticals earlier today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection. Study results show that 92 percent (22 of 24) of patients taking ABT-...
-
Pfizer Lowers 2011 Revenue Guidance to $65.2 - $67.2B
Monday, April 4, 2011 - 7:33am | 49Pfizer (NYSE: PFE) is updating its previous 2011 Reported Revenue guidance range from $66.0 - $68.0 billion to $65.2 - $67.2 billion, and its previous 2012 Reported Revenue target range from $63.0 – $65.5 billion to $62.2 - $64.7 billion, while maintaining all other elements of its 2011 financial...
-
Pfizer to Sell Capsugel to KKR for $2.375B
Monday, April 4, 2011 - 7:31am | 68Pfizer (NYSE: PFE) and Kohlberg Kravis Roberts & Co L.P. (NYSE: KKR) today announced they have entered into an agreement whereby an affiliate of KKR will acquire Pfizer's Capsugel business for $2.375 billion in cash. Capsugel, the world leader in hard capsules and an innovator in drug-delivery...
-
Mylan Receives Approval for Generic Version of Xalatan Ophthalmic Solution
Monday, April 4, 2011 - 7:18am | 60Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Latanoprost Ophthalmic Solution, 0.005%, the generic version of Pharmacia and Upjohn's Xalatan...
-
CEO of Depomed Resigns For Personal Reasons, Replaced By Current Director James Schoeneck (DEPO)
Monday, April 4, 2011 - 7:16am | 466Depomed (NASDAQ: DEPO) today announced the appointment of James A. Schoeneck as the company`s President and CEO, effective April 18, 2011. Mr. Schoeneck, a member of the company`s Board of Directors since 2007, succeeds Carl A. Pelzel, who has resigned for personal reasons. Peter D. Staple,...
-
Pfizer Receives Refusal To File Letter From U.S. FDA On Tafamidis New Drug Application
Monday, April 4, 2011 - 7:16am | 136Pfizer Inc. (NYSE: PFE) announced today that it has received a Refusal to File letter from the United States Food and Drug Administration for tafamidis, the company's novel, oral investigational compound for patients with Transthyretin Familial Amyloid Polyneuropathy. Upon preliminary review, the...
-
HDV: Another Dividend ETF Arrives
Friday, April 1, 2011 - 4:37pm | 506BlackRock, Inc. (BLK) yesterday (3/31/11) launched the iShares High Dividend Equity Fund (HDV). The new ETF provides exposure to high quality income-producing U.S. securities based on the Morningstar Dividend Yield Focus Index. The underlying index seeks to identify companies providing relatively...
-
Axiron Topical Solution CIII Now Available in Pharmacies
Friday, April 1, 2011 - 4:01pm | 61Eli Lilly and Company (NYSE: LLY) announced today that Axiron® (testosterone) topical solution is available in pharmacies throughout the United States. Axiron is a prescription medicine used to treat adult males that have low or no testosterone. Safety and efficacy of Axiron in males younger than...
-
April Catalysts For Biotech And Drug Stocks
Friday, April 1, 2011 - 12:36pm | 781By Brett Chase April is shaping up to be an important month for a number of biotech and drug companies, including some important dates for potentially breakthrough hepatitis C treatments. Here are the key events for some companies. Dates are subject to change. April 5 Optimer Pharmaceuticals (...